KR100475759B1 - 서방형 라놀라진 제형 - Google Patents

서방형 라놀라진 제형 Download PDF

Info

Publication number
KR100475759B1
KR100475759B1 KR10-2001-7003126A KR20017003126A KR100475759B1 KR 100475759 B1 KR100475759 B1 KR 100475759B1 KR 20017003126 A KR20017003126 A KR 20017003126A KR 100475759 B1 KR100475759 B1 KR 100475759B1
Authority
KR
South Korea
Prior art keywords
ranolazine
pharmaceutical formulation
methacrylic acid
formulations
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2001-7003126A
Other languages
English (en)
Korean (ko)
Other versions
KR20010089874A (ko
Inventor
앤드류 에이. 울프
피오나 베이커
존 랜그리지
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
로쉐 팔로 알토 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100475759(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드, 로쉐 팔로 알토 엘엘씨 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20010089874A publication Critical patent/KR20010089874A/ko
Application granted granted Critical
Publication of KR100475759B1 publication Critical patent/KR100475759B1/ko
Assigned to 로쉐 팔로 알토 엘엘씨 reassignment 로쉐 팔로 알토 엘엘씨 권리지분의 전부이전등록 Assignors: 로쉐 팔로 알토 엘엘씨, 씨브이 쎄러퓨틱스, 인코포레이티드
Assigned to 질레드사이언시즈,인코포레이티드 reassignment 질레드사이언시즈,인코포레이티드 권리의 전부이전등록 Assignors: 로쉐 팔로 알토 엘엘씨
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
KR10-2001-7003126A 1998-09-10 1999-09-09 서방형 라놀라진 제형 Expired - Lifetime KR100475759B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US60/099,804 1998-09-10
US09/321,522 1999-05-27
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (2)

Publication Number Publication Date
KR20010089874A KR20010089874A (ko) 2001-10-12
KR100475759B1 true KR100475759B1 (ko) 2005-03-10

Family

ID=26796494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7003126A Expired - Lifetime KR100475759B1 (ko) 1998-09-10 1999-09-09 서방형 라놀라진 제형

Country Status (33)

Country Link
US (14) US6303607B1 (enExample)
EP (3) EP1527779A1 (enExample)
JP (2) JP3745621B2 (enExample)
KR (1) KR100475759B1 (enExample)
CN (2) CN1193757C (enExample)
AR (3) AR022085A1 (enExample)
AT (2) ATE217794T1 (enExample)
AU (4) AU744071B2 (enExample)
BR (2) BR9913626A (enExample)
CA (2) CA2342390C (enExample)
CY (1) CY2008020I2 (enExample)
CZ (2) CZ301375B6 (enExample)
DE (3) DE69901570T2 (enExample)
DK (2) DK1109558T3 (enExample)
ES (2) ES2177346T3 (enExample)
FR (1) FR09C0001I2 (enExample)
GE (1) GEP20053420B (enExample)
HK (1) HK1044284B (enExample)
HU (2) HU224215B1 (enExample)
IL (6) IL141893A0 (enExample)
LU (1) LU91504I2 (enExample)
MX (2) MXPA01002599A (enExample)
NL (1) NL300371I2 (enExample)
NO (4) NO319434B1 (enExample)
NZ (2) NZ510384A (enExample)
PL (3) PL196263B1 (enExample)
PT (2) PT1096937E (enExample)
RU (2) RU2214233C2 (enExample)
SI (2) SI1096937T1 (enExample)
TR (2) TR200101262T2 (enExample)
TW (1) TWI241911B (enExample)
UA (2) UA67793C2 (enExample)
WO (2) WO2000013686A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CN100522169C (zh) * 2005-07-04 2009-08-05 齐鲁制药有限公司 盐酸雷诺嗪缓释制剂及其制备方法
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
EP1998387B1 (en) * 2006-03-17 2015-04-22 Konica Minolta Holdings, Inc. Organic electroluminescent device, display and illuminating device
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407780A2 (en) * 1989-06-23 1991-01-16 Syntex Pharmaceuticals Ltd. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407780A2 (en) * 1989-06-23 1991-01-16 Syntex Pharmaceuticals Ltd. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ainley Wade and Paul J Weller, Handbook of Pharmaceutical Excipients, 1994 *

Also Published As

Publication number Publication date
US20040029890A1 (en) 2004-02-12
UA75027C2 (uk) 2006-03-15
NO20011191D0 (no) 2001-03-08
AU2008207707A1 (en) 2008-09-25
NO320986B1 (no) 2006-02-20
NO2009005I2 (enExample) 2010-06-28
DE69901570T2 (de) 2003-01-09
AU6142599A (en) 2000-03-27
ATE217794T1 (de) 2002-06-15
CZ2001879A3 (cs) 2001-08-15
NO2009005I1 (no) 2009-03-16
CN1354665A (zh) 2002-06-19
IL141892A (en) 2006-08-20
CZ301341B6 (cs) 2010-01-20
JP3745621B2 (ja) 2006-02-15
HUP0104088A2 (hu) 2002-05-29
ATE285774T1 (de) 2005-01-15
PL202207B1 (pl) 2009-06-30
BR9913553A (pt) 2001-10-23
WO2000013687A3 (en) 2000-06-29
NO20054324L (no) 2001-04-30
CA2342390C (en) 2006-08-29
CY2008020I1 (el) 2010-07-28
EP1527779A1 (en) 2005-05-04
DE69922964T2 (de) 2005-12-08
DK1096937T3 (da) 2005-05-09
US20040097514A1 (en) 2004-05-20
UA67793C2 (uk) 2004-07-15
KR20010089874A (ko) 2001-10-12
NZ510386A (en) 2003-08-29
IL180864A0 (en) 2007-07-04
US20060147521A1 (en) 2006-07-06
AU2008207703A1 (en) 2008-09-25
FR09C0001I1 (enExample) 2009-02-27
RU2207856C2 (ru) 2003-07-10
RU2214233C2 (ru) 2003-10-20
DE122008000065I1 (de) 2009-04-09
IL141893A (en) 2008-08-07
US6369062B1 (en) 2002-04-09
US20020090396A1 (en) 2002-07-11
FR09C0001I2 (enExample) 2009-12-18
HK1040060A1 (en) 2002-05-24
US6620814B2 (en) 2003-09-16
WO2000013686A3 (en) 2000-07-06
MXPA01002599A (es) 2005-02-17
WO2000013687A2 (en) 2000-03-16
US20030166659A1 (en) 2003-09-04
IL141893A0 (en) 2002-03-10
NO319434B1 (no) 2005-08-15
AR052921A1 (es) 2007-04-11
HK1044284B (zh) 2005-07-15
AR022085A1 (es) 2002-09-04
SI1096937T1 (en) 2005-04-30
WO2000013686A2 (en) 2000-03-16
TR200101262T2 (tr) 2001-12-21
NL300371I2 (nl) 2009-10-01
PT1109558E (pt) 2002-10-31
EP1109558B1 (en) 2002-05-22
AR053440A2 (es) 2007-05-09
TR200101261T2 (tr) 2002-05-21
CN1193757C (zh) 2005-03-23
PL196668B1 (pl) 2008-01-31
US20060217397A1 (en) 2006-09-28
US6617328B2 (en) 2003-09-09
CZ301375B6 (cs) 2010-02-03
LU91504I2 (fr) 2009-02-03
NZ510384A (en) 2002-10-25
IL141892A0 (en) 2002-03-10
NO20011192D0 (no) 2001-03-08
EP1109558A2 (en) 2001-06-27
TWI241911B (en) 2005-10-21
US20030100566A1 (en) 2003-05-29
DK1109558T3 (da) 2002-08-26
NO20011192L (no) 2001-04-30
DE69922964D1 (de) 2005-02-03
CZ2001880A3 (cs) 2001-08-15
AU6036499A (en) 2000-03-27
US20030099705A1 (en) 2003-05-29
EP1096937A2 (en) 2001-05-09
GEP20053420B (en) 2005-01-25
US6525057B2 (en) 2003-02-25
HU224215B1 (hu) 2005-06-28
NO20011191L (no) 2001-04-30
AU744071B2 (en) 2002-02-14
PL347073A1 (en) 2002-03-11
SI1109558T1 (en) 2002-10-31
HUP0104088A3 (en) 2002-12-28
CY2008020I2 (el) 2010-07-28
MXPA01002598A (es) 2002-04-08
AU760435B2 (en) 2003-05-15
HUP0103844A2 (hu) 2002-04-29
US6852724B2 (en) 2005-02-08
LU91504I9 (enExample) 2019-01-02
ES2177346T3 (es) 2002-12-01
BR9913626A (pt) 2001-12-04
PL196263B1 (pl) 2007-12-31
US6503911B2 (en) 2003-01-07
CA2342390A1 (en) 2000-03-16
US6303607B1 (en) 2001-10-16
US20050059667A1 (en) 2005-03-17
NL300371I1 (nl) 2009-02-02
PT1096937E (pt) 2005-04-29
CN1211086C (zh) 2005-07-20
HUP0103844A3 (en) 2002-11-28
US20050153982A1 (en) 2005-07-14
EP1096937B1 (en) 2004-12-29
CA2343376A1 (en) 2000-03-16
JP2002524416A (ja) 2002-08-06
CN1321088A (zh) 2001-11-07
JP2006096757A (ja) 2006-04-13
HK1044284A1 (en) 2002-10-18
DE69901570D1 (de) 2002-06-27
ES2234302T3 (es) 2005-06-16
CA2343376C (en) 2007-01-09
IL175371A0 (en) 2006-09-05
US20020004506A1 (en) 2002-01-10
US6562826B1 (en) 2003-05-13
EP1096937B9 (en) 2007-02-28
PL348249A1 (en) 2002-05-20
US6864258B2 (en) 2005-03-08

Similar Documents

Publication Publication Date Title
EP1109558B1 (en) Sustained release ranolazine formulations
CA2402222C (en) Sustained release ranolazine formulations
AU2001240092A1 (en) Sustained release ranolazine formulations
HK1075415A (en) Sustained release ranolazine formulations

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20010310

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20010522

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030630

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040212

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040917

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20041217

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20050302

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20050302

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080304

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090227

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20100302

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110321

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20120224

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20130225

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20130225

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20140224

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20140224

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150225

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150225

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20160223

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20160223

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20170227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20170227

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20180226

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20180226

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20190222

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20190222

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20200309

Termination category: Expiration of duration